Philips acquires VitalHealth in further its Population Health technology
Royal Phillips has recently announced the acquisition of VitalHealth, which will enable the business to further develop cloud-based population health management solutions to support the delivery of exceptional, personalised patient care within regional care networks.
Developed by the Mayo Clinic in 2006, VitalHealth’s products and services are now utilised by over 100 healthcare networks within Asia, the US and Europe. Headquartered in the Netherlands, the company aims to further develop solutions as care moves from the hospital to lower cost settings, such as the home, leading to an increased need for a holistic approach to be adopted.
“This acquisition complements our current offering in population health management, and supports our commitment to deliver integrated solutions for care providers and patients to improve people’s health,” commented Carla Kriwet, Chief Business Leader of the Connected Care & Health Informatics Businesses at Royal Philips.
“VitalHealth will help us deliver on that commitment by strengthening our offering for care coordination, outcome management and patient engagement.”
Population health management will become a proactive approach to improve and reduce health costs, and will involve the aggregation of patient data across multiple health IT sources.
Additionally, smart analytics will be utilised to gain increased understanding surrounding the health needs of the population and the coordination of care within that population, providing engagement with each individual patient to improve both clinical and financial outcomes.
- Aetna discusses the affects of escalating healthcare costs worldwide
- Ascension and Providence St Joseph could be the US’ next biggest health merger
- Nokia look at how blockchain will transform the management of health data
“It will accelerate our mission to enable better health for millions of people around the world,” added Laurens van der Tang, CEO of VitalHealth.
“Our digital health solutions are highly complementary to the ones that Philips provides. Together, we have the potential to become the undisputed global leader in population health management.”
VitalHealth has a successful portfolio of telehealth applications to give patients the tools they need to play a more active role in their own care with the ability aggregate data from different information systems to provide quick insights into the total population. The combined portfolios will therefore support healthcare providers to identify and manage high-risk, high-cost patient populations.
Furthermore, VitalHealth’s platform will strengthen Philips’ HealthSuite digital platform, the company’s digital enabler for the next generation of connected health solutions.
The move will also complement its recent acquisition of US start-up Analytical Informatics, Inc., which will support the expansion of its Radiology Solutions.
“Integrating Analytical Informatics’ software tools and applications into our current offerings will enable us to accelerate the delivery of next-generation technology, software and services, to bring the power of operational intelligence and decision support to radiology,” commented Sham Sokka, General Manager of Radiology Solutions at Philips.
“We’ll be in an even stronger position to provide our customers with a host of solutions and help them maximise opportunities to do more with less, while delivering patient-centric care.”
Introducing Dosis - the AI powered dosing platform
Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works.
When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing.
The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced.
What is the Strategic Anemia Advisor?
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease.
SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool.
What else is Dosis working on?
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs.
What are Dosis' strategic goals for the next 2-3 years?
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.
What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.